natgillin/translations-raw huggingface dataset:
Related to glycopyrronium 
V povezavi z glikopironijem
Adrenal suppression1 
občasni trombocitopenija1
How to store Riarify 
Shranjevanje zdravila Riarify
It is important that you take your dose as advised by your doctor. 
Če ste uporabili večji odmerek zdravila Riarify, kot bi smeli Pomembno je, da uporabite odmerek, ki vam ga je svetoval zdravnik.
After dispensing, the inhaler may be stored at a temperature up to 25°C for a maximum of 2 months. 
Po izdaji lahko inhalator shranjujete največ 2 meseca pri temperaturi do 25 °C.
LIST OF EXCIPIENTS 
ŠTEVEC ODMERKOV
For glycopyrronium, the maximum plasma concentration was similar after administration of the fixed or extemporary combination, while the systemic exposure was slightly higher after administration of Riarify than with the extemporary combination. 
Za glikopironij je bila največja koncentracija v plazmi podobna po dajanju fiksne kombinacije ali trojne kombinacije, ki je bila sestavljena iz fiksne kombinacije beklometazondipropionata in formoterola plus glikopironija,
• medicines for treating Parkinson's disease (levodopa), to treat an underactive thyroid gland (levothyroxine), medicines containing oxytocin (which causes uterine contraction) and alcohol can increase the chances of formoterol side effects on the heart. 
• zdravili za zdravljenje Parkinsonove bolezni (levodopa), zmanjšanega delovanja ščitnice (levotiroksin), zdravili, ki vsebujejo oksitocin (ta povzroči krčenje maternice), in alkoholom lahko poveča možnost, da formoterol povzroči neželene učinke na srce; • zaviralci monoaminoksidaze, vključno z zdravili, ki imajo podobne lastnosti kot furazolidon in prokarbazin in se uporabljajo za zdravljenje duševnih motenj, lahko povzroči zvišanje krvnega tlaka;
IMPORTANT: steps 2 to 5 should not be performed too quickly: Patients should remove the protective cap from the mouthpiece and check that the mouthpiece is clean and free from dust and dirt or any other foreign objects. 
Bolnik naj z ustnika sname zaščitni pokrovčekin preveri, ali je ustnik čist in brez prahu ali umazanije od drugih predmetov.
Glaucoma1, cataract1 
neznana pogostnost glavkom1, katarakta1
• fungal infections of the vagina 
• glivične okužbe nožnice;
Store at 25°C for a maximum of 2 months. 
Shranjujte največ 2 meseca pri temperaturi 25 °C.
The daily dose of Riarify corresponds to a medium dose of inhaled corticosteroid; furthermore, these effects are much less likely to occur than with oral corticosteroids. 
Dnevni odmerek zdravila Riarify ustreza srednjemu odmerku inhalacijskega kortikosteroida.
• if you have an eye problem called narrow-angle glaucoma. 
• če imate težavo z očmi, imenovano glavkom z zaprtim zakotjem;
Use with a spacer 
Pot uporabe
Among the observed adverse reactions the following are typically associated with: 
Možni sistemski učinki vključujejo:
Store at 25°C for a maximum of 4 months. 
Shranjujte največ 4 mesece pri temperaturi 25 °C.
• increased blood flow to some tissues in the body 
• povečan pretok krvi v nekaterih tkivih telesa; • kašelj in produktivni kašelj;
• tiredness 
• driska;
D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 
POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN
Oedema peripheral1 
občasni astenija redki periferni edem1
• swallowing difficulties 
• težave s požiranjem;
Atrial fibrillation, electrocardiogram QT prolonged, tachycardia, tachyarrhythmia1, palpitations 
Srčne bolezni atrijska fibrilacija, podaljšanje intervala QT na elektrokardiogramu, tahikardija, tahiaritmija1, palpitacije občasni angina pektoris (stabilna1 in nestabilna), ventrikularne ekstrasistole1, nodalni ritem, sinusna bradikardija redki
• tooth decay 
• suha usta;
You should get a replacement when the counter or indicator shows the number 20. 
Ko števec ali kazalnik odmerkov pokaže številko 20, morate dobiti nov inhalator.
EXPIRY DATE 
Datum izdaje:
Hyperaemia1, flushing1, hypertension 
Žilne bolezni hiperemija1, vročinski oblivi1, hipertenzija občasni ekstravazacija krvi redki
Hypokalaemia may increase the disposition towards arrhythmias in patients who are treated with digitalis glycosides. 
Pri bolnikih, zdravljenih z digitalisovimi glikozidi, lahko hipokaliemija poveča nagnjenost k motnjam srčnega ritma.
Compared with tiotropium, Riarify improved pre-dose FEV1 by 51 mL after 26 weeks of treatment and by 61 mL after 52 weeks of treatment. 
26-tedenskem zdravljenju in za 61 ml po 52-tedenskem zdravljenju.
• inflammation of the kidneys. 
• vnetje ledvic.
The combination of Riarify with some other COPD medicines or medicines such as diuretics (medicines that make the body lose water, to treat heart disease or high blood pressure), can cause a sharp fall in your blood level of potassium. 
Kombinacija zdravila Riarify z nekaterimi drugimi zdravili za KOPB ali zdravili, kot so npr. diuretiki (zdravili za odvajanje vode,
• dizziness 
• drhtenje;
B. PACKAGE LEAFLET 
Zunanja ovojnina skupnega pakiranja
Related to beclometasone dipropionate 
V povezavi z beklometazondipropionatom
• sensation of a missed heart beat, unusually slow heart beat 
• občutek izpuščenega srčnega utripa,
Pressurised inhalation, solution (pressurised inhalation). 
inhalacijska raztopina pod tlakom Brezbarvna do rumenkasta raztopina.
Vascular disorders 
KAZALNIK ODMERKOV
The elimination half-life of grapiprant is approximately 4.6 to 5.67 hours. 
Razpolovni čas izločanja grapipranta je približno 4,6 do 5,67 ure.
The tablet can be divided into equal halves. 
Tableto je mogoče razdeliti na dve enaki polovici.
A clinical response to treatment is usually seen within 7 days. 
Klinični odziv na zdravljenje se običajno pokaže v 7 dneh.
This difference in favour of Galliprant was statistically significant (p-value= 0.0008). 
Ta razlika v korist zdravila Galliprant je bila statistično značilna (vrednost p = 0,0008).
26 Rue de la Chapelle 68330 Huningue France 
26 Rue de la Chapelle 68330 Huningue Francija
Duration of treatment will depend on the response observed to treatment. 
Trajanje zdravljenja je odvisno od opaženega odziva na zdravljenje.
100 mg For the full list of excipients, see section 6.1. 
100 mg Za celoten seznam pomožnih snovi glejte poglavje 6.1.
Approximately 70-80% of the administered dose is excreted within 48-72 h with the majority of the dose excreted unchanged. 
Približno 70-80 % uporabljenega odmerka se izloči v 4872 urah, pri čemer se večina odmerka izloči v nespremenjeni obliki.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 09/01/2018 
Datum pridobitve dovoljenja za promet: 09/01/2018
No gender related differences in absorption are observed. 
Razlik v absorpciji, povezanih s spolom živali, niso opazili.
If you notice any side effects, even those not already listed in this package leaflet or you think the medicine has not worked, please inform your veterinary surgeon. 
Če opazite kakršne koli neželene učinke, tudi tiste, ki niso navedeni v tem navodilu za uporabo, ali mislite, da zdravilo ni delovalo, obvestite svojega veterinarja.
Administer this veterinary medicinal product on an empty stomach (e.g. in the morning) and at least one hour before the next meal, once daily at a target dose of 2 mg per kg body weight. 
Zdravilo dajte na prazen želodec (npr. zjutraj) in vsaj eno uro pred naslednjim obrokom, enkrat dnevno v priporočenem odmerku 2 mg na kilogram telesne mase.
The safety of the veterinary medicinal product has not been established in dogs under 9 months of age and in dogs weighing less than 3.6 kg. 
Varnost tega zdravila pri psih, mlajših od 9 mesecev in psih, ki tehtajo manj kot 3,6 kg, ni bila ugotovljena.
One bottle per cardboard box. 
Ena plastenka v kartonski škatli.
EU/2/17/221/001 (20 mg, 7 tablets, 20 ml bottle) EU/2/17/221/002 (20 mg, 30 tablets, 20 ml bottle) EU/2/17/221/003 (60 mg, 7 tablets, 20 ml bottle) EU/2/17/221/004 (60 mg, 30 tablets, 35 ml bottle) EU/2/17/221/005 (100 mg, 7 tablets, 35 ml bottle) EU/2/17/221/006 (100 mg, 30 tablets, 60 ml bottle) 
EU/2/17/221/001 (20 mg, 7 tablet, 20 ml plastenka) EU/2/17/221/002 (20 mg, 30 tablet, 20 ml plastenka) EU/2/17/221/003 (60 mg, 7 tablet, 20 ml plastenka) EU/2/17/221/004 (60 mg, 30 tablet, 35 ml plastenka) EU/2/17/221/005 (100 mg, 7 tablet, 35 ml plastenka) EU/2/17/221/006 (100 mg, 30 tablet, 60 ml plastenka)
As field studies were limited to 28 days, longer-term treatment should be considered carefully and regular monitoring undertaken by the veterinarian. 
Ker je bila izvedba terenskih študij omejena na 28 dni, dlje trajajoče zdravljenje zahteva skrben razmislek in redno spremljanje s strani veterinarja.
If no clinical improvement is apparent after 14 days, treatment with Galliprant should be discontinued and different treatment options should be explored in consultation with the veterinarian. 
Če po 14 dneh ne pride do kliničnega izboljšanja, je treba zdravljenje z zdravilom Galliprant ukiniti in v posvetu z veterinarjem proučiti druge možnosti zdravljenja.
SPECIAL STORAGE CONDITIONS Do not store above 30 °C. 
POSEBNA NAVODILA ZA SHRANJEVANJE Ne shranjujte pri temperaturi nad 30 °C.
In case of overdose, symptomatic treatment should be initiated. 
V primeru prevelikega odmerjanja je treba uvesti simptomatsko zdravljenje.
The veterinary medicinal product is available in the following pack sizes: 
Zdravilo je na voljo v naslednjih velikostih pakiranja:
If signs of sulphonamide hypersensitivity occur, treatment should be discontinued. 
Če se pojavijo znaki preobčutljivosti na sulfonamide, je treba zdravljenje ukiniti.
The mean percentage of unbound grapiprant was 4.35% and 5.01% at a grapiprant concentration of 200 ng/ml and 1000 ng/ml. 
Povprečen odstotek nevezanega grapipranta je bil 4,35 % oziroma 5,01 % pri koncentraciji grapipranta 200 ng/ml oziroma 1000 ng/ml.
Do not use in case of hypersensitivity to the active substance or any of the excipients. 
Ne uporabite v primerih preobčutljivosti na učinkovino ali na katero koli pomožno snov.
QM01AX92 
Oznaka ATC vet: QM01AX92
Maximum grapiprant concentrations are observed in serum within one hour of dosing in the fasted state. 
Najvišje koncentracije grapipranta v serumu nastopijo v eni uri po odmerjanju na tešče.
It is not known whether dogs with a history of hypersensitivity to sulphonamides will exhibit hypersensitivity to grapiprant. 
Ni znano, ali psi z anamnezo preobčutljivosti na sulfonamide izkazujejo preobčutljivost na grapiprant.
Drug compatibility should be monitored in animals requiring adjunctive therapy. 
Pri živalih, ki potrebujejo dodatno zdravljenje, je treba spremljati kompatibilnost zdravil.
Four metabolites are identified and the metabolic pathways include Ndeamination to form the major metabolite in faeces (7.2%) and urine (3.4%). 
Ugotovljeni so štirje presnovki, presnovne poti pa vključujejo N-deaminacijo, pri kateri nastaja glavni presnovek v blatu (7,2 %) in urinu (3,4 %).
The concurrent use of grapiprant with other anti-inflammatory agents has not been studied and should be avoided. 
Sočasna uporaba grapipranta z drugimi protivnetnimi zdravili ni bila proučena in se ji je treba izogibati.
Intake of the tablet with food reduces the oral bioavailability, i.e. the oral bioavailability of grapiprant when taken in the fasted state was 89% and when taken with food it was 33%, with mean Cmax and AUC grapiprant values reduced 4-fold and 2-fold, respectively. 
Zaužitje tablete s hrano zmanjša peroralno biološko razpoložljivost, t. j. peroralna biološka razpoložljivost grapipranta je bila pri dajanju na tešče 89 %, pri dajanju s hrano pa 33 %, pri čemer sta se vrednosti Cmax in AUC grapipranta znižali za 4-krat oziroma 2-krat.
After a single oral dose of 2 mg grapiprant/kg, Cma x and AUC values of 1.21 µg/ml and 2.71 µg.h/ml were reached in the fasted state. 
Po enkratnem peroralnem odmerku 2 mg grapipranta/kg v stanju teščosti sta bili doseženi vrednosti Cmax 1,21 µg/ml in AUC 2,71 µg.h/ml.
Do not use this veterinary medicinal product after the expiry date, which is stated on the carton and bottle after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na škatli in plastenki za oznako »EXP«.
Faecal excretion accounted for roughly 65% of the dose whereas approximately 20% of the dose was excreted through urine. 
Približno 65 % odmerka se je izločilo z blatom, približno 20 % pa z urinom.
Dose range (mg/kg bw) 
Razpon odmerka (mg/kg t. m.)
The pharmacological activity of the metabolites is not known. 
Farmakološka aktivnost teh presnovkov ni znana.
In dogs, grapiprant is a major excretion product in bile, faeces and urine. 
Pri psih je grapiprant glavni produkt izločanja v žolču, blatu in urinu.
CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES 7 tablets 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ODMERKOV 7 tablet
- common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports). 
- pogosti (pri več kot 1, toda manj kot 10 živalih od 100 zdravljenih živali) - občasni (pri več kot 1, toda manj kot 10 živalih od 1.000 zdravljenih živali) - redki (pri več kot 1, toda manj kot 10 živalih od 10.000 zdravljenih živali)
Prior treatment with other anti-inflammatory substances may result in additional or increased severity of adverse effects and accordingly a treatment-free period with such drugs should be observed before the commencement of treatment with this veterinary medicinal product. 
Predhodno zdravljenje z drugimi protivnetnimi zdravili lahko privede do dodatnih neželenih učinkov ali povečane resnosti neželenih učinkov, zato mora po zdravljenju s tovrstnimi zdravili in pred začetkom zdravljenja s tem zdravilom preteči interval brez zdravljenja.
The specific effects of the binding of prostaglandin E2 to the EP4 receptor include vasodilation, increased vascular permeability, angiogenesis and production of pro‐inflammatory mediators. 
Specifični učinki vezave prostaglandina E2 na receptor EP4 vključujejo vazodilacijo, povečano žilno prepustnost, angiogenezo in tvorbo vnetnih mediatorjev.
Commonly used protein-bound veterinary medicinal products include cardiac, anticonvulsant and behavioural medications. 
Pogosto uporabljana zdravila, ki se vežejo na beljakovine, vključujejo zdravila za srce, antiepileptike in zdravila za vedenjske motnje.
The concomitant use of protein-bound veterinary medicinal products with grapiprant has not been studied. 
Sočasna uporaba grapipranta in zdravil, ki se vežejo na beljakovine, ni bila proučena.
MARKETING AUTHORISATION NUMBER(S) EU/2/17/221/006 (100 mg, 30 tablets, 60 ml bottle) 
ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET EU/2/17/221/006 (100 mg, 30 tablet, 60 ml plastenka)
Grapiprant is readily and rapidly absorbed from the gastrointestinal tract in dogs. 
Grapiprant se zlahka in zelo hitro absorbira iz prebavil psov.
One white HDPE bottle with a child-resistant cap containing 7 or 30 tablets (20 mg, 60 mg or 100 mg tablets). 
Ena bela plastenka iz HDPE z za otroke varno zaporko, ki vsebuje 7 ali 30 tablet (20 mg, 60 mg ali 100 mg tablete).
In clinical studies, the following mild and generally transient adverse reactions have been observed: vomiting, soft-formed faeces, diarrhoea and inappetence. 
V kliničnih študijah so opazili naslednje blage in na splošno prehodne neželene učinke: bruhanje, zmehčano blato, diarejo in neješčnost.
4.2 Indications for use, specifying the target species For the treatment of pain associated with mild to moderate osteoarthritis in dogs. 
4.2 Indikacije za uporabo pri ciljnih živalskih vrstah Za zdravljenje bolečine, povezane z blagim do zmernim osteoartritisom pri psih.
INDICATION(S) For the treatment of pain associated with mild to moderate osteoarthritis in dogs. 
INDIKACIJA(E) Za zdravljenje bolečine, povezane z blagim do zmernim osteoartritisom pri psih.
The majority of clinical cases assessed in the clinical field studies suffered from mild to moderate osteoarthritis based on the veterinary assessment. 
Pri večini kliničnih primerov, ki so bili obravnavani v kliničnih terenskih študijah, je po veterinarski oceni šlo za blag do zmeren osteoartritis.
The treatment-free period should take into account the pharmacokinetic properties of the products used previously. 
Dolžina intervala brez zdravljenja je odvisna od farmakokinetičnih lastnosti predhodno uporabljenih zdravil.
To achieve a substantiated response to treatment, use the veterinary medicinal product only in mild and moderate cases of osteoarthritis. 
Da bi dosegli opazen odziv na zdravljenje, uporabljajte zdravilo samo v primerih blagega do zmernega osteoartritisa.
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reactions during the course of one treatment) 
Pogostost neželenih učinkov je določena po naslednjem dogovoru: - zelo pogosti (neželeni učinki se pokažejo pri več kot 1 od 10 zdravljenih živali)
From the two clinical field studies, the overall success rates based on CBPI (Canine Brief Pain Inventory, as completed by the owner) at 28 days after the start of the treatment, were 51.3% (120/235) for Galliprant and 35.5% (82/231) for the placebo group. 
(Canine Brief Pain Inventory, ki ga je izpolnil lastnik psa) 28 dni po začetku zdravljenja 51,3 % (120/235) za skupino, zdravljeno z zdravilom Galliprant, in 35,5 % (82/231) za skupino, zdravljeno s placebom.
Grapiprant is primarily bound to serum proteins. 
Grapiprant se primarno veže na beljakovine v serumu.
EU/2/17/221/001-006 
ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET EU/2/17/221/001-006
Grapiprant is a selective antagonist of the EP4 receptor, a key prostaglandin E2 receptor that predominantly mediates prostaglandin E2‐elicited nociception. 
Grapiprant je selektivni antagonist receptorja EP4, ključnega receptorja prostaglandina E2, ki pretežno posreduje nociocepcijo, ki jo izzove prostaglandin E2.
Pack sizes of 7 and 30 tablets per bottle. 
Velikosti pakiranja: 7 in 30 tablet v plastenki.
Mild decreases in serum albumin and total protein, most often within the reference range, have been observed in dogs treated with grapiprant but were not associated with any clinically significant observations or events. 
Pri psih, zdravljenih z grapiprantom, so opazili blaga znižanja albumina in skupnih beljakovin v serumu, najpogosteje v referenčnem razponu, ki pa niso bila povezana s klinično pomembnimi opažanji ali dogodki.
PACKAGE SIZE 7 tablets 
VELIKOST PAKIRANJA 7 tablet
Any remaining whole and half tablets should be discarded after 3 months following first opening. 
Neporabljene cele tablete in polovice tablet je treba zavreči 3 mesece po prvem odprtju.
The following number of tablets should be given once daily: 
Enkrat dnevno je treba dati naslednje število tablet: Telesna masa (kg)
The EP4 receptor is important in mediating pain and inflammation as it is the primary mediator of the prostaglandin E2-elicited sensitization of sensory neurons and prostaglandin E2-elicited inflammation. 
Receptor EP4 je pomemben pri posredovanju bolečine in vnetja, saj je primarni mediator senzitizacije senzoričnih nevronov in vnetja, ki ju izzove prostaglandin E2.
Wash hands after handling of the veterinary medicinal product. 
Po rokovanju s tem zdravilom si umijte roke.
Use with caution in dogs suffering from pre-existing liver, cardiovascular or renal dysfunctions or from gastrointestinal disease. 
Uporabljajte previdno pri psih z obstoječimi okvarami jeter, srca in ožilja ali ledvic ali boleznimi prebavil.
Any half tablets should be stored in the bottle. 
Neporabljene polovice tablet je treba shraniti v plastenki.
Pharmacotherapeutic group: Other anti-inflammatory and antirheumatic agents, non-steroids ATCvet code: 
Farmakoterapevtska skupina: Druge nesteroidne protivnetne in protirevmatične učinkovine
Grapiprant does not accumulate in the dog after repeated administration. 
Grapiprant se pri ponavljajočem se dajanju ne kopiči v psu.
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Cardboard box (20 ml, 35 ml and 60 ml bottles) 
PODATKI NA ZUNANJI OVOJNINI Kartonska škatla (20 ml, 35 ml in 60 ml plastenke)
Any remaining whole and half tablets should be discarded after 3 months following first opening of the bottle. 
Neporabljene cele tablete in polovice tablet je treba zavreči 3 mesece po prvem odprtju plastenke.
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Veterinary medicinal product subject to prescription. 
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE Rp-Vet.
Shelf-life after first opening of the bottle: 3 months. 
Rok uporabnosti po prvem odpiranju stične ovojnine: 3 mesece.
In vitro protein binding of grapiprant indicates that grapiprant is primarily bound to dog serum albumin. 
Vezava grapipranta na beljakovine in vitro kaže, da se grapiprant pri psih primarno veže na albumin v serumu.
In healthy dogs treated with grapiprant for 9 consecutive months, mild and transient soft-formed or mucous faeces, occasionally bloody, and vomiting were observed at daily overdoses of approximately 2.5x and 15x the recommended dose. 
Pri zdravih psih, ki so 9 mesecev zaporedoma prejemali prevelike odmerke grapipranta, ki so presegali največji priporočen odmerek za približno 2,5-krat in 15-krat, so opazili blag in prehoden pojav zmehčanega ali sluzastega blata, ki je bilo občasno krvavo, ter bruhanje.
Since clinical signs of canine osteoarthritis wax-and-wane, intermittent treatment may be beneficial in some dogs. 
Zaradi izmenične krepitve in slabitve kliničnih znakov osteoartritisa pri psih je pri nekaterih psih lahko koristno občasno zdravljenje.
In case of accidental ingestion by children, mild and reversible gastrointestinal signs and nausea may be observed. 
Če otrok nenamerno zaužije to zdravilo,se lahko pojavijo blagi prehodni gastrointestinalni znaki in slabost.
MANUFACTURER'S BATCH NUMBER Lot {number} 
PROIZVAJALČEVA ŠTEVILKA SERIJE Lot: {številka}
QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: 
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Induction sealed, white, round high density polyethylene (HDPE) bottles (20, 35, and 60 ml) with a threaded child-resistant cap with rayon coil. 
Indukcijsko zatesnjene, bele okrogle plastenke iz polietilena velike gostote (HDPE) (20, 35 in 60 ml) z za otroke varno navojno zaporko, z zvitkom iz rajona.
Vomiting was observed very commonly, whereas soft-formed faeces, diarrhoea and inappetence were commonly observed. 
Bruhanje so opazili zelo pogosto, zmehčano blato, diarejo in neješčnost pa pogosto.
PACKAGE SIZE 30 tablets 
VELIKOST PAKIRANJA 30 tablet
Grapiprant is a non-steroidal, non-cyclooxygenase inhibiting anti-inflammatory drug in the piprant class. 
Grapiprant je nesteroidno protivnetno zdravilo iz razreda piprantov, ki ne zavira ciklooksigenaze.
In very rare cases, haematemesis or haemorrhagic diarrhoea was reported following clinical use post authorisation in the USA. 
Pri klinični uporabi po odobritvi v ZDA,so v zelo redkih primerih poročali o hematemezi ali hemoragični driski.
Two hydroxylated metabolites and one N-oxidated metabolite are also recovered in bile, faeces and/or urine. 
V žolču, blatu in/ali urinu je mogoče odkriti še dva hidroksilirana presnovka in en N-oksidiran presnovek.
4.7 Use during pregnancy, lactation or lay Do not use in pregnant, lactating or breeding animals as the safety of grapiprant has not been established during pregnancy and lactation or in dogs used for breeding. 
Ne uporabite pri živalih v obdobju brejosti ali laktacije ali pri živalih, namenjenih za vzrejo, saj varnost grapipranta v obdobju brejosti in laktacije ali pri psih, namenjenih za vzrejo, ni bila ugotovljena.
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE Bottle (60 ml) 
PODATKI, KI MORAJO BITI NAVEDENI NA STIČNI OVOJNINI Plastenka (60 ml)
EXPIRY DATE EXP {month/year} Once opened use by: 
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA EXP: {mesec/leto}
Do not use in pregnant, lactating or breeding animals. 
Ne uporabite pri živalih v obdobju brejosti ali laktacije ali pri živalih, namenjenih za vzrejo.
ROUTE(S) OF ADMINISTRATION Oral use 
NAČIN IN POT(I) UPORABE